ECE2020 Oral Communications Diabetes, Obesity, Metabolism and Nutrition (7 abstracts)
Supplementation with Bifidobacterium breve BR03 and Bifidobacterium breve B632 favoured weight loss and improved insulin metabolism in children and adolescents with obesity in the BIFI-OBESE cross-over, randomized placebo-controlled trial
Arianna Solito 1 , Iderina Hasballa 2 , Matteo Calgaro 3 , Nicole Bozzi Cionci 4 , Roberta Ricotti 1 , Marina Caputo 2 , Giulia Genoni 1 , Alice Monzani 1 , Francesca Archero 1 , Simonetta Bellone 1 , Gianni Bona 1 , Emanuela Agosti 5 , Gianluca Aimaretti 2 , Angela Amoruso 6 , Marco Pane 6 , Nicola Vitulo 3 , Diana Di Gioia 4 & Flavia Prodam 7
1SCDU Pediatrics, University of Piemonte Orientale, Department of Health Sciences, Novara, Italy; 2SCDU Endocrinology, University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy; 3University of Verona, Department of Biotechnology, Verona, Italy; 4University of Bologna, Department of Agricultural and Food Sciences, Bologna, Italy; 5University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy; 6Probiotical Research Srl, Novara, Italy; 7University of Piemonte Orientale, Department of Health Sciences, Novara, Italy
Background: Variations in gut microbiota might impact metabolic functions like caloric intake and energy expenditure leading to body weight excess. Microbiota modulation may be a potential approach for obesity management, especially in subject characterized by specific microbial enterotypes.
Objective: We aimed to assess the impact of probiotic treatment in obese children and adolescents, under diet control, on weight loss, glucose, and insulin homeostasis, gut microbiota composition and SCFAs.
Methods: This was a cross-over, double-blind, RCT on 100 children and adolescents (6–18 years) affected by obesity with insulin-resistance (NCT03261466). The subjects on dietary training were randomized to treatment with 2 × 109 CFU/AFU/die of Bifidobacterium breve BR03 (DSM 16604) and Bifidobacterium breve B632 (DSM 24706) or placebo for 8 weeks with a 4-weeks wash-out period. Clinical, biochemical and stool sample analyses were carried out at each time (T0–T3).
Results: At baseline, there were no differences in clinical and metabolic parameters between treatment and control group, except Escherichia coli concentration, which was higher in the placebo group. A mixed-effect model analysis revealed a carry-over effect on most of the variables, suggesting that the probiotic treatment had a prolonged effect over the washout period. Due to this event, only the results of the first phase (T0–T1) were deeply analyzed. For all the subjects (active and placebo) we observed significantly decreased BMI, BMI Z score, waist circumference (WC), systolic and diastolic blood pressure, insulin after OGTT, and E. Coli concentrations at T1. Probiotics further decreased WC (−3.51 cm, P < 0.05), BMI Z score (−0.17 kg/m2, P = 0.07), fasting insulin (−4.57 mcUI/ml, P = 0.06), HOMA IR (−1.1, P < 0.05), E. Coli concentrations (P < 0.02), and increased nearly to significance insulin sensitivity after OGTT. No differences were observed in inflammatory cytokines and GLP-1 levels at fasting. Of twenty-five SCFAs, probiotics decreased the 2-methyl- propanoic acid relative abundance (P < 0.02). The PCoA analysis of SCFAs allowed defining four clusters of patients. Two clusters identified subjects that were healthier and had better responses in BMI Z score, WC, insulin resistance and sensitivity during probiotics.
Conclusions: Probiotic supplementation with B. breve BR03 and B632 has determined beneficial effects on weight and insulin metabolism in obese children and adolescents undergoing dietary training. Moreover, the microbiome-host configuration could be a predictor of the obesity phenotype and the efficacy of treatment with B. Breve strains.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more